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mouse genome sequence with a dense 
map of markers already genotyped for the 
majority of inbred strains require only in 
silico analyses without genotyping eﬀorts 
and with a resolution that can lead to the 
single gene.
In conclusion, even if the discovery of 
genes underlying QTLs has been proven 
to be extremely diﬃcult, recent advances 
in the mouse genome and the availabil-
ity of particular new mouse strains such 
as CSSs leave promising expectations for 
the near future. Moreover, the choice of 
using molecular phenotypes, such as the 
COLI kidney deposition, that are likely to 
be closer to pathogenic mechanisms rather 
than more complex clinical phenotypes 
such as proteinuria and renal failure, makes 
the trait chosen by Kato and colleagues7 a 
more tractable problem with high potential 
for shedding light on molecular pathways 
regulating the most important phenom-
enon in progression to end-stage renal 
failure: interstitial ﬁbrosis.
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Role for alkaline phosphatase 
as an inducer of vascular 
calcification in renal failure?
M Schoppet1 and CM Shanahan2
Vascular calcification is associated with increased cardiovascular 
morbidity and mortality. A number of calcification inhibitors have been 
defined recently, including inorganic pyrophosphate (PPi), an important 
physicochemical inhibitor of hydroxyapatite crystal growth. Increased 
hydrolysis of PPi by tissue-nonspecific alkaline phosphatase (TNAP) may 
occur in renal failure and act to enhance mineralization of vessels.
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Heterotopic, extraosseous vascular cal-
cification, a phenomenon known for 
decades, was once regarded as a passive 
physicochemical process triggered by 
excess calcium and phosphate exceeding 
the solubility threshold, resulting in pre-
cipitation and apatite mineral deposition 
in vessels and soft tissues. Over recent 
years, this concept has been challenged 
by a variety of in vitro and in vivo models 
of vascular calciﬁcation, especially tar-
geted gene deletion studies in animals, 
which have demonstrated that minerali-
zation is controlled by a balance between 
procalcific and anticalcific regulatory 
proteins acting locally in the vessel wall 
and/or systemically in the circulation. 
Alterations in this balance induced by 
injury, disease, or genetic deﬁciency are 
postulated to favor heterotopic mineral 
deposition.1 Further evidence support-
ing the hypothesis of calcification as 
an active, cell-mediated process comes 
from the observed similarities between 
vascular calciﬁcation and endochondral 
and intramembranous mineralization in 
bone. Thus, the molecular events induc-
ing extracellular matrix mineralization 
may be the same in both physiologi-
cal and pathological processes. Indeed, 
within calcifying vascular specimens, 
cells that are reminiscent of osteoblasts, 
chondrocytes, or osteoclasts have been 
detected, derived either from stem cells 
(circulating or local cells) or from pheno-
typic transdiﬀerentiation of vessel wall-
resident cells such as vascular smooth 
muscle cells. Furthermore, transcription 
factors and cytokines with crucial roles in 
bone homeostasis have been detected in 
calciﬁed vascular lesions,1 suggesting that 
mineralization of vessels may be triggered 
through similar molecular mechanisms 
and signaling pathways.
The study by Lomashvili et al.2 (this 
issue) has investigated the role of 
tissue-nonspeciﬁc alkaline phosphatase 
(TNAP) in the pathogenesis of vascu-
lar calciﬁcation. The authors show that 
TNAP is upregulated under uremic con-
ditions in vessels from rats, which leads 
to the hydrolysis and therefore inactiva-
tion of inorganic pyrophosphate (PPi), 
a potent inhibitor of hydroxyapatite 
crystal growth and a potential local and 
circulating inhibitor of vascular calciﬁ-
cation. Although the possibility that the 
TNAP/PPi system is involved in vascu-
lar calciﬁcation is intriguing, what is the 
evidence for its role or expression in the 
vascular system?
Firstly, the ectoenzymes PC-1/
nucleotide pyrophosphatase phospho-
diesterase 1 (NPP1), which hydrolyzes 
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adenosine 5′-triphosphate (ATP) to gen-
erate PPi, and TNAP are both present on 
the plasma membrane of calcifying cells3 
and act to tightly regulate tissue levels of 
PPi. PPi, which is a substrate for alkaline 
phosphatases, is a small molecule that 
binds to nascent hydroxyapatite crys-
tals and prevents further incorporation 
of inorganic phosphate (Pi) ions into 
these crystals. PPi is present in almost 
all extracellular matrices, and both in 
vitro and in vivo studies have shown the 
potential for PPi to prevent pathological 
mineralization. In animal models, vascu-
lar calciﬁcation was induced by lowering 
of the levels of PPi, for example in mice 
carrying the ank mutation (a transmem-
brane transporter protein that shuttles 
PPi between intracellular and extracel-
lular compartments) or in NPP1–/– mice, 
which exhibit cartilage-specific gene 
expression changes in their vasculature. 
Moreover, heritable deﬁciency of NPP1 
in humans has been demonstrated to be 
the cause of idiopathic infantile arterial 
calciﬁcation, a disease aﬀecting children 
that is associated with severe medial calci-
ﬁcation of arteries.3 Further indirect evi-
dence for a protective role of PPi comes 
from other rat models of vascular calciﬁ-
cation induced by the vitamin K antago-
nist warfarin or toxic doses of vitamin D. 
Bisphosphonates, nonhydrolyzable pyro-
phosphate analogs, prevented mineraliza-
tion of vessels, potentially by binding to 
microcalciﬁcations early in the calciﬁca-
tion process.4 However, bisphosphonates 
have also been found to stimulate release 
of a serum mineral complex containing 
matrix Gla protein (MGP) and fetuin-A, 
both potent inhibitors of vascular cal-
cification. Additionally, MGP inhibits 
bone morphogenetic protein-2 (BMP2) 
induction of alkaline phosphatase activ-
ity;5 therefore, the mechanisms involved 
in this inhibition by bisphosphonates 
remain controversial (Figure 1).
Alkaline phosphatases themselves 
comprise a heterogeneous group of 
dimeric metalloenzymes that have a 
wide tissue distribution but are particu-
larly concentrated in the liver, kidney, 
or bone. They are encoded by at least 
four diﬀerent gene loci—namely, tissue-
nonspeciﬁc, intestinal, placental, and 
germ-cell alkaline phosphatase—with 
post-translational modifications of 
the tissue-nonspeciﬁc isoenzyme pro-
ducing liver, kidney, and bone forms 
of the enzyme. Alkaline phosphatases 
have dual functions, acting to catalyze 
the hydrolysis of phosphomonoesters 
with the release of Pi as well as acting 
as pyrophosphatases to hydrolyze PPi; 
however, their functions outside bone 
are poorly understood. They appear to 
be able to act on bone both locally and 
systemically. Increased serum levels of 
a soluble form of TNAP are associated 
with altered osteoblast activity and bone 
disease. Conceivably, the circulating 
form of TNAP could also aﬀect vascu-
lar mineralization, although increasing 
the serum concentration of circulating 
TNAP in normophosphatemic mice did 
not induce heterotopic mineralization 
of any tissue.6 In patients with hyper-
phosphatasia, a group of disorders that 
also feature elevated serum TNAP activ-
ity, such as Paget’s disease of bone, there 
are preliminary studies, but, to date, no 
clear evidence for an association with 
vascular calciﬁcation. This may indicate 
that only membrane-bound TNAP plays 
a role in vascular calciﬁcation, or that 
other vascular-specific cofactors are 
necessary to induce vascular calciﬁca-
tion in the context of elevated TNAP. 
Since physiological TNAP function 
takes place in bone, whereas TNAP 
expression is not bone specific, this 
suggests that the spatial restriction of 
extracellular matrix mineralization to 
bone could be explained by additional 
requirements. One such component was 
postulated to be collagen I expression by 
osteoblasts.6 The only tissues in which 
both collagen I and TNAP are physi-
ologically coexpressed are bone and 
teeth. Interestingly, in vitro, the extracel-
lular matrix produced by rapidly miner-
alizing vascular cells was also found to 
contain higher amounts of collagen I 
than non-mineralizing cells.7
TNAP expression favors bone min-
eralization by removal of PPi from the 
extracellular milieu. The defective min-
eralization of bone in TNAP deﬁciency 
can be corrected solely by reduction 
of PPi levels. However, we have less 
Figure 1 | Possible mechanism for TNAP-induced vascular calcification. Alkaline phosphatases 
are membrane-anchored ectoenzymes that catalyze the hydrolysis of inorganic pyrophosphate 
(PPi), small molecules made of two phosphate ions linked by an ester bond that bind to nascent 
hydroxyapatite crystals and prevent further incorporation of inorganic phosphate (Pi) ions into 
these crystals. Tissue-nonspecific alkaline phosphatase (TNAP) is induced by bone morphogenetic 
protein-2 (BMP2) and vitamin D agents that induce osteo/chondrogenic transdifferentiation of 
vascular smooth muscle cells. Uremia may be another condition to induce TNAP. PPi is released by 
vascular smooth muscle cells via Ank, a protein that shuttles intracellular PPi to the extracellular 
milieu. The enzyme PC-1/nucleotide pyrophosphatase phosphodiesterase 1 (NPP1) can generate 
PPi via hydrolysis of adenosine 5′-triphosphate (ATP). Mineral deposition may also be inhibited by 
bisphosphonates, PPi analogs. Collagen I, a cofactor for tissue mineralization in orthotopic bone 
formation, may play a role in vascular calcification as well. Matrix Gla protein (MGP), which can be 
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information about TNAP and PPi in the 
vasculature. Studies have shown that 
TNAP is upregulated in vitro during phe-
notypic transdiﬀerentiation of vascular 
smooth muscle cells into osteogenic cells 
induced by β-glycerophosphate, which 
in turn is associated with downregula-
tion of smooth muscle lineage markers.8 
Furthermore, TNAP was found to be 
expressed in calciﬁed vessels of patients 
and colocalized with osteo/chondro-
genic transcription factors that regulate 
expression of the gene.1
The study by Lomashvili et al.2 supports 
and extends these studies, strengthening 
the contention of a role of TNAP/PPi in 
uremic vascular calciﬁcation. However, 
there still remain a number of unanswered 
questions. Although the study investi-
gated the role of TNAP in vascular cal-
ciﬁcation, the animal model used did not 
induce vascular calciﬁcation. In fact, the 
authors mention that aortic calciﬁcation 
was not seen with their diet. Therefore, 
the link between vascular calciﬁcation 
and upregulation of TNAP is hard to 
prove. Previous studies have shown that 
injury is required to induce TNAP in 
vessels and to inhibit PPi; however, in 
this model, uremia was suﬃcient only to 
induce TNAP. This strongly suggests that 
reduction of PPi in the context of vascular 
injury may be required for calciﬁcation, 
and studies to investigate this idea would 
be important. Also, it may be that TNAP 
has distinct functions not only related to 
hydrolysis of PPi, especially if its upregula-
tion occurs prior to osteo/chondrogenic 
diﬀerentiation. The authors did not show 
that interfering with the supposed patho-
mechanism could rescue animals from 
vascular calciﬁcation, which would sup-
port their concept. For example, it would 
have been interesting to see if chondro-
genic conversion of vascular smooth 
muscle cells occurred in this model, as 
was seen in NPP1–/– animals. As TNAP 
plays a major role in bone homeostasis, 
one may wonder whether, in the animals, 
TNAP was increased in serum or indeed 
other tissues by uremia, and whether 
this had any eﬀects on bone formation. 
Furthermore, what were the circulating 
levels of PPi in the animals? Circulating 
levels of PPi are reduced in renal-failure 
patients, as shown by the same group;9 
however, a direct relationship between this 
reduction and vascular calciﬁcation has 
not yet been shown. Although decreased 
PPi levels may contribute to vascular cal-
ciﬁcation in this patient group, the source 
of circulating PPi may not be the vascular 
system, and it is unclear whether lower 
circulating levels of PPi reﬂect increased 
TNAP activity in the vessel wall. These 
important questions could potentially be 
answered in a slightly modiﬁed animal 
model and would be highly informative.
Strategies aimed at selective inhibition 
of TNAP may have clinical beneﬁts in vas-
cular calciﬁcation, although other organ 
systems such as bone may be adversely 
aﬀected, and it seems not entirely clear 
whether the role of TNAP is conserved 
between mice and humans. Alternatively, 
PPi analogs such as bisphosphonates 
developed for osteoporosis might be 
optimized for activities that inhibit vas-
cular calciﬁcation. To date, the eﬃcacy of 
bisphosphonates has not been proved in 
large prospective trials enrolling patient 
cohorts with vascular calciﬁcation, and 
smaller studies have yielded ambiguous 
results. Of note, new compounds that 
block the hydrolytic pyrophosphatase 
capacity of TNAP have been developed 
that were eﬀective in an in vitro system 
and also in an ex vivo animal model to 
inhibit calcification.10 Greater under-
standing of both the mechanisms and 
the clinical consequences of vascular 
calciﬁcation may aid the development of 
future therapies more eﬀectively designed 
and applied to inhibit or even reverse 
the deleterious clinical consequences 
of the condition. The TNAP/PPi system 
may be a potential candidate to link the 
combined phenotype of osteoporosis 
and vascular calciﬁcation, entities that 
may share a common pathomechanism. 
The idea that treatment might be feasible 
is perhaps premature. Systemic vascular 
treatment may prove diﬃcult, and other 
enzymes, not targeted by speciﬁc inhibi-
tors of TNAP, may also be involved in 
regulation of PPi levels.
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